Camurus is a Swedish specialty pharmaceutical company focused on long-acting injectable medicines based on its FluidCrystal depot technology. Its products and pipeline target conditions such as opioid dependence and endocrine disorders, aiming for less frequent dosing than daily oral therapy. Customers are primarily healthcare systems, clinics and patients who benefit from sustained-release formulations developed in-house or with partners.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 553.1 | — | 147 | — |
| Q1 2025 | 558.3 | — | 197.3 | 159.3% |
| Q2 2025 | 675.5 | — | 244.8 | 233.6% |
| Q4 2025 | 464.5 | -16% | 100.9 | -31.4% |
| Q1 2026 | 533.1 | -4.5% | 143.8 | -27.1% |
| Q2 2026 | 702.1 | 3.9% | 240.8 | -1.6% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Pandox AB (publ) (PNDX B), Sinch AB (publ) (SINCH), Alleima AB (publ) (ALLEI), BioArctic AB (publ) (BIOA B), Munters Group AB (publ) (MTRS), Clas Ohlson AB (publ) (CLAS B)